173 related articles for article (PubMed ID: 38297333)
1. Adverse clinical outcomes and immunosuppressive microenvironment of RHO-GTPase activation pattern in hepatocellular carcinoma.
Yang Q; Zhuo Z; Qiu X; Luo R; Guo K; Wu H; Jiang R; Li J; Lian Q; Chen P; Sha W; Chen H
J Transl Med; 2024 Jan; 22(1):122. PubMed ID: 38297333
[TBL] [Abstract][Full Text] [Related]
2. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
3. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatic analysis of RHO family of GTPases identifies RAC1 pharmacological inhibition as a new therapeutic strategy for hepatocellular carcinoma.
Bayo J; Fiore EJ; Dominguez LM; Cantero MJ; Ciarlantini MS; Malvicini M; Atorrasagasti C; Garcia MG; Rossi M; Cavasotto C; Martinez E; Comin J; Mazzolini GD
Gut; 2021 Jul; 70(7):1362-1374. PubMed ID: 33106353
[TBL] [Abstract][Full Text] [Related]
5. Analysis of angiogenesis-related subtypes of hepatocellular carcinoma and tumor microenvironment infiltration feature in hepatocellular carcinoma.
Li W; Wu R; Zhang S; Zhao Y; Li L; Hu Z; Su Q; Mang Y; Zhang X; Dong Y; Zheng K; Ran J; Li L
Clin Transl Oncol; 2023 Jul; 25(7):2099-2115. PubMed ID: 36708372
[TBL] [Abstract][Full Text] [Related]
6. ECT2 regulates the Rho/ERK signalling axis to promote early recurrence in human hepatocellular carcinoma.
Chen J; Xia H; Zhang X; Karthik S; Pratap SV; Ooi LL; Hong W; Hui KM
J Hepatol; 2015 Jun; 62(6):1287-95. PubMed ID: 25617497
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive study based on exosome-related immunosuppression genes and tumor microenvironment in hepatocellular carcinoma.
Yang Z; Li X; Pan C; Li Y; Lin L; Jin Y; Zheng J; Yu Z
BMC Cancer; 2022 Dec; 22(1):1344. PubMed ID: 36550445
[TBL] [Abstract][Full Text] [Related]
8. Integrated investigation of the clinical implications and targeted landscape for RNA methylation modifications in hepatocellular carcinoma.
Zhang J; Gao J; Hu M; Xu S; Cheng C; Zheng W; Zhang J
Eur J Med Res; 2023 Jan; 28(1):46. PubMed ID: 36707911
[TBL] [Abstract][Full Text] [Related]
9. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract][Full Text] [Related]
10. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma.
Xu G; Jiang Y; Li Y; Ge J; Xu X; Chen D; Wu J
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16261-16277. PubMed ID: 37698679
[TBL] [Abstract][Full Text] [Related]
11. Single-cell RNA sequencing highlights the role of PVR/PVRL2 in the immunosuppressive tumour microenvironment in hepatocellular carcinoma.
Li A; Ji B; Yang Y; Ye B; Zhu Q; Hu X; Liu Y; Zhou P; Liu J; Gao R; Zhou Q; Kang B; Jiang Y
Front Immunol; 2023; 14():1164448. PubMed ID: 37383234
[TBL] [Abstract][Full Text] [Related]
12. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
Huang X; Qiu Z; Li L; Chen B; Huang P
Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
[TBL] [Abstract][Full Text] [Related]
13. Identification and immunoprofiling of key prognostic genes in the tumor microenvironment of hepatocellular carcinoma.
Wang T; Chen B; Meng T; Liu Z; Wu W
Bioengineered; 2021 Dec; 12(1):1555-1575. PubMed ID: 33955820
[TBL] [Abstract][Full Text] [Related]
14. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Liu R; Liu Y; Zhang F; Wei J; Wu L
Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
[TBL] [Abstract][Full Text] [Related]
15. A Novel hepatocellular carcinoma specific hypoxic related signature for predicting prognosis and therapeutic responses.
Cai G; Zhu J; Ning D; Li G; Zhang Y; Xiong Y; Liang J; Yu C; Chen X; Liang H; Ding Z
Front Immunol; 2022; 13():997316. PubMed ID: 36059442
[TBL] [Abstract][Full Text] [Related]
16. An independent poor-prognosis subtype of hepatocellular carcinoma based on the tumor microenvironment.
Wang J; Lou J; Fu L; Jin Q
J Int Med Res; 2021 Feb; 49(2):300060520980646. PubMed ID: 33567957
[TBL] [Abstract][Full Text] [Related]
17. Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma.
Zhang X; Zhuge J; Liu J; Xia Z; Wang H; Gao Q; Jiang H; Qu Y; Fan L; Ma J; Tan C; Luo W; Luo Y
Front Immunol; 2023; 14():1153423. PubMed ID: 37006285
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation-mediated silencing of matricellular protein dermatopontin promotes hepatocellular carcinoma metastasis by α3β1 integrin-Rho GTPase signaling.
Fu Y; Feng MX; Yu J; Ma MZ; Liu XJ; Li J; Yang XM; Wang YH; Zhang YL; Ao JP; Xue F; Qin W; Gu J; Xia Q; Zhang ZG
Oncotarget; 2014 Aug; 5(16):6701-15. PubMed ID: 25149533
[TBL] [Abstract][Full Text] [Related]
19. An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents.
Moeini A; Torrecilla S; Tovar V; Montironi C; Andreu-Oller C; Peix J; Higuera M; Pfister D; Ramadori P; Pinyol R; Solé M; Heikenwälder M; Friedman SL; Sia D; Llovet JM
Gastroenterology; 2019 Nov; 157(5):1383-1397.e11. PubMed ID: 31344396
[TBL] [Abstract][Full Text] [Related]
20. Rho GTPases in hepatocellular carcinoma.
Grise F; Bidaud A; Moreau V
Biochim Biophys Acta; 2009 Apr; 1795(2):137-51. PubMed ID: 19162129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]